Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis

Blood blood.2024027287.

https://doi.org/10.1182/blood.2024027287

Published: 2025

Includes: Supplemental data

Journal Articles

Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT

Nicola Polverelli, Juan Carlos Hernandez-Boluda, Francesco Onida, Carmelo Gurnari, Kavita Raj, Tomasz Czerw, Michelle Kenyon, Marie Robin, Katja Sockel, Annalisa Ruggeri, Isabel Sánchez-Ortega, Daniel A. Arber, Luca Arcaini, Fernando Barroso Duarte, Giorgia Battipaglia, Yves Chalandon, Fabio Ciceri, Nicholas C.P. Cross, Joanna Drozd-Sokolowska, Vaneuza Araújo Moreira Funke, Nico Gagelmann, Naseema Gangat, Jason Gotlib, Paola Guglielmelli, Claire N. Harrison, Gabriela S Hobbs, Tania Jain, Joseph D. Khoury, Jean-Jacques Kiladjian, Nicolaus Kröger, Luca Malcovati, Massimo Martino, Ruben Mesa, Attilio Orazi, Eric Padron, Francesca Palandri, Francesco Passamonti, Mrinal M. Patnaik, Naveen Pemmaraju, Deepti H. Radia, Andreas Reiter, Domenico Russo, Christof Scheid, Ayalew Tefferi, Alessandro M. Vannucchi, Daniel Howard Wiseman, Ibrahim Yakoub-Agha, Donal P McLornan

Blood blood.2024028000.

https://doi.org/10.1182/blood.2024028000

Published: 2025

Includes: Supplemental data

Journal Articles

Clinical-genomic profiling of MDS to inform allo-HSCT:Recommendations from an international panel on behalf of the EBMT

Blood blood.2024025131.

https://doi.org/10.1182/blood.2024025131

Published: 2025

Includes: Supplemental data

Journal Articles

The Premature Reduction of Venetoclax in an Initial Cycle of Ven-AZA Regimen for Unfit AML Patients Leads to Shortened Overall Survival - a Retrospective Study of Polish Adult Leukemia Group (PALG)

Blood (2024) 144 (Supplement 1): 2854.

https://doi.org/10.1182/blood-2024-208144

Published: 2024

Journal Articles

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia - a Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Blood (2024) 144 (Supplement 1): 600.

https://doi.org/10.1182/blood-2024-198075

Published: 2024

Journal Articles

Central Nervous System Disorders (CNSD) Following Hematopoietic Stem Cell Transplantation (HSCT): A Prospective Study from the Infectious Diseases Working Party (IDWP) and the Transplant Complications Working Party (TCWP), European Society of Blood and Marrow Transplantation (EBMT)

Blood (2024) 144 (Supplement 1): 3497.

https://doi.org/10.1182/blood-2024-194695

Published: 2024

Journal Articles

Impact of Donor Type on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis

Blood (2024) 144 (Supplement 1): 3559.

https://doi.org/10.1182/blood-2024-193992

Published: 2024

Journal Articles

Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques

Blood (2024) 144 (Supplement 1): 3558.

https://doi.org/10.1182/blood-2024-200237

Published: 2024

Journal Articles

MRD-Driven Venetoclax and Rituximab Combination in Previously Untreated Chronic Lymphocytic Leukemia: First Results of the Prospective, Multicenter, Phase II Trial of the Polish Adult Leukemia Group (VERITA PALG-CLL5)

Blood (2024) 144 (Supplement 1): 3242.

https://doi.org/10.1182/blood-2024-201076

Published: 2024

Journal Articles

Decreased Chronic GvHD with Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelofibrosis Allografted with Unrelated Donor: A Study from the Chronic Malignancies Working Party of the EBMT

Blood (2024) 144 (Supplement 1): 4894.

https://doi.org/10.1182/blood-2024-203487

Published: 2024

Journal Articles

Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Neoplasms with Accompanying Paroxysmal Nocturnal Hemoglobinuria - a Study on Behalf of Cmwp and Saawp of the EBMT

Blood (2024) 144 (Supplement 1): 4949.

https://doi.org/10.1182/blood-2024-203009

Published: 2024

Journal Articles

Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome in Young Adults. a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Blood (2024) 144 (Supplement 1): 4939.

https://doi.org/10.1182/blood-2024-193963

Published: 2024

Journal Articles

Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?

Blood (2024) 144 (4): 445–456.

https://doi.org/10.1182/blood.2023022273

Published: 2024

Includes: Supplemental data

Journal Articles

Salvage Transplant Versus CAR-T Cell Therapy for Relapsed Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3592.

https://doi.org/10.1182/blood-2023-184945

Published: 2023

Journal Articles

Allogeneic Hematopoietic Cell Transplantation for Vexas Syndrome: Results of a Multicenter Study from the Chronic Malignancies and Autoimmune Disease Working Parties of the EBMT

Blood (2023) 142 (Supplement 1): 708.

https://doi.org/10.1182/blood-2023-174385

Published: 2023

Journal Articles

Conditioning Intensity in Patients Aged > 50 Years Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrom: A Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Blood (2023) 142 (Supplement 1): 472.

https://doi.org/10.1182/blood-2023-172796

Published: 2023

Journal Articles

The Outcome of the First-Line Therapy of Patients with Follicular Lymphoma during COVID-19 Pandemic. a Real-World Data from the Polish Lymphoma Research Group (PLRG)

Blood (2023) 142 (Supplement 1): 1679.

https://doi.org/10.1182/blood-2023-186945

Published: 2023

Journal Articles

Cryopreserved Versus Non-Cryopreserved Peripheral Blood Haematopoietic Stem Cells for Autologous Stem Cell Transplantation in Multiple Myeloma: A Comparative Analysis from the Chronic Malignancies Working Party of EBMT and WBMT

Blood (2023) 142 (Supplement 1): 1034.

https://doi.org/10.1182/blood-2023-182808

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelodysplastic Neoplasms Allografted with an Unrelated Donor: A Registry Study of the Chronic Malignancies Working Party of the EBMT

Blood (2023) 142 (Supplement 1): 898.

https://doi.org/10.1182/blood-2023-178287

Published: 2023

Journal Articles

Impact of Post-Transplant Cyclophosphamide (PTCY)-Based Prophylaxis in Matched Sibling Donor Allo-HCT for Patients with Myelodysplastic Syndrome: A Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Blood (2023) 142 (Supplement 1): 4938.

https://doi.org/10.1182/blood-2023-174609

Published: 2023

NARROW

Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis

Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT

Clinical-genomic profiling of MDS to inform allo-HSCT:Recommendations from an international panel on behalf of the EBMT

The Premature Reduction of Venetoclax in an Initial Cycle of Ven-AZA Regimen for Unfit AML Patients Leads to Shortened Overall Survival - a Retrospective Study of Polish Adult Leukemia Group (PALG)

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia - a Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Central Nervous System Disorders (CNSD) Following Hematopoietic Stem Cell Transplantation (HSCT): A Prospective Study from the Infectious Diseases Working Party (IDWP) and the Transplant Complications Working Party (TCWP), European Society of Blood and Marrow Transplantation (EBMT)

Impact of Donor Type on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis

Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques

MRD-Driven Venetoclax and Rituximab Combination in Previously Untreated Chronic Lymphocytic Leukemia: First Results of the Prospective, Multicenter, Phase II Trial of the Polish Adult Leukemia Group (VERITA PALG-CLL5)

Decreased Chronic GvHD with Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelofibrosis Allografted with Unrelated Donor: A Study from the Chronic Malignancies Working Party of the EBMT

Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Neoplasms with Accompanying Paroxysmal Nocturnal Hemoglobinuria - a Study on Behalf of Cmwp and Saawp of the EBMT

Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome in Young Adults. a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?

Salvage Transplant Versus CAR-T Cell Therapy for Relapsed Multiple Myeloma

Allogeneic Hematopoietic Cell Transplantation for Vexas Syndrome: Results of a Multicenter Study from the Chronic Malignancies and Autoimmune Disease Working Parties of the EBMT

Conditioning Intensity in Patients Aged > 50 Years Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrom: A Study on Behalf of the Chronic Malignancies Working Party of the EBMT

The Outcome of the First-Line Therapy of Patients with Follicular Lymphoma during COVID-19 Pandemic. a Real-World Data from the Polish Lymphoma Research Group (PLRG)

Cryopreserved Versus Non-Cryopreserved Peripheral Blood Haematopoietic Stem Cells for Autologous Stem Cell Transplantation in Multiple Myeloma: A Comparative Analysis from the Chronic Malignancies Working Party of EBMT and WBMT

Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelodysplastic Neoplasms Allografted with an Unrelated Donor: A Registry Study of the Chronic Malignancies Working Party of the EBMT

Impact of Post-Transplant Cyclophosphamide (PTCY)-Based Prophylaxis in Matched Sibling Donor Allo-HCT for Patients with Myelodysplastic Syndrome: A Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only